相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U. Platzbecker et al.
BLOOD (2019)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
Guillermo Garcia-Manero et al.
LEUKEMIA RESEARCH (2018)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Implications of molecular genetic diversity in myelodysplastic syndromes
Rafael Bejar
CURRENT OPINION IN HEMATOLOGY (2017)
Myelodysplastic syndromes: Contemporary review and how we treat
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G. Garcia-Manero et al.
LEUKEMIA (2016)
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Guillermo Garcia-Manero et al.
BLOOD (2016)
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Hyun Ae Jung et al.
ONCOTARGET (2015)
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Eric Laille et al.
PLOS ONE (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes
Yogen Saunthararajah
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
Lieke H. van der Helm et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome
Jose Ramon Gonzalez-Porras et al.
CANCER (2011)
Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications
Ali Al Ameri et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Carlo Stresemann et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G)
PS Brucker et al.
EVALUATION & THE HEALTH PROFESSIONS (2005)
Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
AJG Jansen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications
V Santini et al.
ANNALS OF INTERNAL MEDICINE (2001)
分享论文
